"The U.S. Food and Drug Administration (FDA) along with the Centers for Disease Control and Prevention (CDC) and state and local officials are investigating a multi-state outbreak of Cyclospora infections. We are moving quickly to learn as much as"...
Ceftriaxone Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ceftriaxone (ceftriaxone sodium and dextrose) Injection is an antibacterial drug used to treat conditions such as lower respiratory tract infections, skin and skin structure infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, and meningitis. It is available in generic form. Common side effects of Ceftriaxone include rash, diarrhea, nausea, blood clots, dizziness, and headache.
The recommended dose of Ceftriaxone is 1 to 2 grams once per day. Do not exceed 4 grams in one day. Talk to your doctor about your individual dosage recommendation. There are no known drugs that interact with Ceftriaxone. Tell your doctor all medications you are taking and if you have a history of gastrointestinal disease or gallbladder disease. If you are pregnant, only use Ceftriaxone if clearly needed. Exercise caution if you are taking Ceftriaxone while breastfeeding.
Our Ceftriaxone (ceftriaxone sodium and dextrose) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ceftriaxone FDA Prescribing Information: Side Effects
Ceftriaxone (ceftriaxone sodium and dextrose injection ) Sodium is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Ceftriaxone (ceftriaxone sodium and dextrose injection ) Sodium therapy or of uncertain etiology, were observed:
LOCAL REACTIONS — Phlebitis was reported in < 1% after IV administration.
HYPERSENSITIVITY — rash (1.7%). Less frequently reported ( < 1 %) were pruritus, fever or chills.
HEMATOLOGIC — eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported ( < 1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.
GASTROINTESTINAL — diarrhea (2.7%). Less frequently reported ( < 1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).
RENAL — elevations of the BUN (1.2%). Less frequently reported ( < 1 %) were elevations of creatinine and the presence of casts in the urine.
CENTRAL NERVOUS SVSTEM — headache or dizziness were reported occasionally ( < 1%).
GENITOURINARY — moniliasis or vaginitis were reported occasionally ( < 1 %).
MISCELLANEOUS — diaphoresis and flushing were reported occasionally ( < 1%).
Other rarely observed adverse reactions ( < 0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.
Read the entire FDA prescribing information for Ceftriaxone (Ceftriaxone Sodium and Dextrose Injection )
Additional Ceftriaxone Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.